Prevention of hev-blue light-induced skin lipofuscin accumulation with a triasorb-containing formulation

Summary: Abstract Body: Lipofuscin is a fluorescent pigment made of oxidized proteins and lipids which accumulate during natural or accelerated cell aging. Keratinocytes exposed to UVA and High Energy Blue Light (HEBL) are known to suffer expressive damages in lysosomes and to accumulate lipofuscin. In here, we aim to report whether fibroblasts exposed to UVA and HEBL also accumulates lipofuscin. We also aim to test the efficacy of a TriAsorB-containing formulation (F1) to avoid lipofuscin accumulation in keratinocytes and fibroblasts. Fibroblasts exposed to UVA (356nm; 15 J/cm2), violet (410nm; 30J/cm2) or blue (450nm; 110J/cm2) light shows significant increase in lipofuscin accumulation, as demonstrated by the integration of the intracellular fluorescent signals of lipofuscin pigments (lesc=488nm, lemi>522nm), as well as by Sudan-Black staining. The quantum efficiencies of lipofuscin accumulation in skin fibroblasts exposed, respectively to UVA, violet and blue photons, considering the lipofuscin quantification, and the relatives’ photon energies, sun irradiances and skin penetrations, shows the ratio of 1.0:1.1:0.6. So, anti-aging strategies related with sun exposure must offer equilibrated protection in the UVA and visible ranges. Then, we compared the accumulation of lipofuscin in cells whose wells were not protected, with those that were protected with F1 or with placebo formulations. Uncontrolled and placebo showed similar levels of lipofuscin accumulation. F1 formulation protected both keratinocytes and fibroblasts from lipofuscin accumulation. The efficiencies of protection of the F1 formulation varied from 80 to 95%. TriAsorB offers broadband protection extending to the HEV-Blue light range, significantly avoiding the accumulation of lipofuscin and consequently efficiently avoiding the sun-induced photoaging. Carlos MV Palomino², Patrick Bogdanowicz¹, Katherine Tsantarlis², Carine JACQUES-JAMIN¹, Gautier Doat³, Camille Boudet³, Sandrine Bessou-Touya¹, Hélène Duplan¹, Maurício da Silva Baptista² 1. Recherche Pharmaco-Clinique, Pierre Fabre Dermo-Cosmetique SAS, Toulouse, Occitanie, France. 2. Departamento de Bioquímica, Universidade de Sao Paulo, São Paulo, SP, Brazil. 3. Laboratoires Avène, Lavaur, France. UV Biology/Injury and Non-melanoma Cancers